Description
Pinealon is a synthetic tripeptide bioregulator with the sequence Glu-Asp-Arg (EDR), developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Despite its name suggesting pineal gland origin, Pinealon was derived from brain cortex extract research. The same Cortexin-based work that produced Cortagen. The two compounds differ by a single amino acid at the C-terminus: Cortagen carries proline (AEDP), Pinealon carries arginine (EDR as a tripeptide). Pinealon enters neuronal cell nuclei and modulates gene expression through direct peptide-DNA interaction. Its documented specialty research targets include antioxidant enzyme expression, MAPK/ERK signaling timing, and cell cycle regulatory proteins in CNS cell models.
Key Characteristics
- SOD2 and GPx1 antioxidant enzyme upregulation is the primary documented gene expression finding. Pinealon increases expression of these mitochondrial and cytoplasmic antioxidant enzymes in neuronal models, reducing oxidative stress markers independently of receptor-mediated signaling
- MAPK/ERK timing modulation is a distinctive research finding. Pinealon delays ERK1/2 activation from approximately 2.5 to 20 minutes under oxidative stress conditions; this timing shift is mechanistically specific and distinguishes Pinealon research from compounds that simply increase or decrease ERK pathway activity
- PCNA and p21 expression modulation — these cell cycle regulatory proteins are relevant to neuroregeneration research; their modulation connects Pinealon to cell cycle biology in neuronal populations, extending its research scope beyond antioxidant effects
- A single-amino-acid difference from Cortagen creates a natural SAR pairing. Cortagen (AEDP) and Pinealon (EDR) share the Khavinson brain cortex research origin and the same intranuclear DNA-binding mechanism, but their C-terminal residue difference (Pro vs Arg) is associated with different gene expression profiles, making them a useful comparative pair for structure-activity studies
- All published evidence is preclinical and concentrated within the Khavinson research network. No independent Western clinical trials have been conducted
Handling and Storage
Store as lyophilized powder under refrigeration, away from heat, moisture, and light. As a tripeptide, Pinealon is susceptible to proteolytic degradation under suboptimal conditions. Reconstitute immediately before use and avoid repeated freeze-thaw cycles.
FAQs
What is Pinealon?
Pinealon (EDR) is a synthetic tripeptide bioregulator from the Khavinson series, derived from brain cortex extract research despite its pineal-referencing name. It targets neuronal cell nuclei through direct peptide-DNA interaction and modulates antioxidant enzyme gene expression (SOD2, GPx1), MAPK/ERK signaling timing, and cell cycle regulatory proteins (PCNA, p21) in CNS preclinical models. All evidence is preclinical.
How does Pinealon differ from Cortagen within the Khavinson CNS series?
Both originate from brain cortex research and operate through the same intranuclear DNA-binding mechanism. The structural difference is a single amino acid. Cortagen ends in proline (AEDP tetrapeptide), Pinealon ends in arginine (EDR tripeptide). This difference is associated with distinct gene expression profiles. Cortagen’s research focuses on cortical neuron gene regulation and BDNF expression in hippocampal tissue, while Pinealon’s documented targets center on antioxidant enzyme upregulation and MAPK/ERK timing modulation.
Why is MAPK/ERK timing modulation significant in Pinealon research?
The finding is not simply that Pinealon increases or decreases ERK1/2 activity. It shifts the timing of ERK activation under oxidative stress from approximately 2.5 minutes to 20 minutes. Timing of MAPK cascade activation determines downstream gene expression outcomes. Earlier activation drives different cellular responses than delayed activation. This temporal shift is mechanistically specific to Pinealon. It is relevant in research designs examining how the timing of stress-response signaling, rather than its magnitude, affects neuronal outcome in oxidative challenge models.
